We detected an increased intratumor abundance of them under diabetic conditions and could show that one of the best-known advanced glycogen end products, CML, activates oncogenic and inflammatory pathways in breast cancer cells, in line with RAGE signaling. This evidence concerns the gene AGER and chronic myelogenous leukemia, BCR-ABL1 positive.